摘要
目的了解视网膜母细胞瘤(RB)组织癌-睾丸抗原(CTA)基因NY-ESO-1的表达,探讨这些基因成为RB特异性免疫治疗靶抗原的可能性。方法选15例人RB组织和12例非肿瘤病变视网膜组织及22例正常眼部组织(对照组),采用逆转录-聚合酶链反应(RT-PCR)技术研究上述组织NY-ESO-1的mRNA表达情况,并根据肿瘤病理分级、肿瘤大小、临床分期等临床指标进行统计学分析。结果 15例RB组织中,NY-ESO-1的表达率分别为40%(6/15);NY-ESO-1基因在12例非肿瘤病变视网膜组织及22例正常眼部组织中均不表达。结论 NY-ESO-1基因在RB组织中有一定频率的表达,NY-ESO-1的表达率与病人的性别、年龄和临床分期,肿瘤大小及病理分级均无相关性(P>0.05)。NY-ESO-1有希望成为RB特异性免疫治疗的靶抗原。
Objective To detect the mRNA expression of the CTA （NY-ESO-1） in retinoblastoma （RB） tissues and investigate the possibility of applying this antigen as the target antigen for RB specific immunotherapy. Methods With reverse-transcription polymerase chain reaction （RT-PCR）, the mRNA expression of NY-ESO-1 in 15 cases of RB tissues, 12 cases of nontumoreus retina tissues and 22 cases of normal ocular region tissues were detected. The results of expression and related clinical parameters Were analyzed with statistic analysis software. Results Among 15 cases of RB tissues, NY-ESO-1 mRNA was detected in 40% （6/15）, NY-ESO-1 can＇ t be detected in the 12 cases of nontumomus retina tissues and 22 cases of normal ocular region tissues. Conclusion With expressive frequency in RB, no relationship was found between the expression of NY-ESO-1 genes and related clinical parameters （P 〉 0. 05）. NY-ESO-1 might be potential target antigen for specific immunotherapy of RB.
出处
《中国临床新医学》
2010年第6期511-514,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
广西自然科学基金(桂科青0542052)
